RE: Parsortix - FDA approval limitations28 Feb 2023 12:30
JTT,
Screening is a completely different entity, and If you look Grail are head and shoulders above competitors in that field. The numbers required 100s of thousands of participants means this is not a good idea for angle to persue due to the £10s of millions involved.
Just recently attended an excellent lecture about this, got to hand it to Grail, they have done/are doing the studies and will likely reap the reward here. Plenty of money in diagnostics and disease monitoring which is where Angle’s product sits…. Without having to test 100000 punters to prove efficacy!